News & Media

Hemostemix and Ludwig Boltzmann Institute for Experimental and Clinical Traumatology Enter Into Research Collaboration Agreement to Develop Hemostemix Regenerative Technology
Jun 17 2015 -

Calgary, Alberta

Hemostemix Inc. (the “Corporation”) (TSX-V: “HEM”) announced today that it has entered into a research collaboration agreement with the Austria-based Ludwig Boltzmann Institute for Experimental and Clinical Traumatology (“LBI”) to explore applications of Hemostemix technology for restoring blood supply. LBI is an internationally renowned organization dedicated to research in the fields of tissue engineering, stem cells, and regenerative medicine. 

“Collaborating with the Ludwig Boltzmann Institute gives Hemostemix an opportunity to explore in depth the mechanism of action of its lead product ACP-01 for a refined understanding of how ACP-01 fundamentally works to improve blood flow,” said Dr. Ina Sarel, vice president of research and development at Hemostemix. “We value LBI’s expertise with novel preclinical models that enable us to optimize future applications for ACP-01.”

“This research collaboration agreement comes at the right time in the growth of Hemostemix,” said Dr. Elmar Burchardt, president and CEO of Hemostemix. “With our multicenter, double-blind, and placebo-controlled phase-2 trial of ACP-01 for critical limb ischemia in progress across international sites under the same clinical protocol, the scientific expertise of the Ludwig Boltzmann Institute will help us develop Hemostemix technology for novel therapeutic applications. Furthermore, demonstrating the mechanism of action of ACP-01 will make Hemostemix more attractive to commercial partners.”

About the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology

Based in Vienna, Austria, the Ludwig Boltzmann Institute (LBI) for Experimental and Clinical Traumatology offers state-of-the-art facilities for tissue engineering, including stem-cell research. With its full translational approach and an interdisciplinary team of surgeons, life scientists, and engineers, it provides an optimal research environment in the areas of neuroregeneration, soft-tissue repair, and cartilage and bone regeneration. The LBI facilities feature cell culture laboratories with all associated monitoring capabilities, including flow cytometry, molecular biology, microarray, laser-scanning confocal microscopy, biomaterial characterization, and preclinical in vivo facilities, including full microsurgical setup and extensive imaging capabilities. For more information, visit trauma.lbg.ac.at/en/about-us.

For more information, please contact  office@hemostemix.com

Back to Overview